Antibody specialist Affitech AB acquired the full rights to diabody technology originally owned by Pharmexa A/S, the Danish immunotherapy and vaccine company. No financial details were disclosed.
Dibodies, or bi-specific single chain antibodies, are recombinant antibody-like proteins that are relevant to a number of therapeutic areas. Affitech’s decision to acquire the technology follows on from a license to the technology taken out in 2007. Affitech CEO Martin Welschof said the dibody technology complements the Affitech’s antibody discovery platform. “We are delighted to have this technology under our total ownership, which will benefit both our proprietary programmes and our collaborations with pharma and biotech companies. In addition we will continue to pursue sublicensing arrangements with third parties.”
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
